Ye Fei, Xie Da-xing, Lu Yun-ping, Gao Qing-lei
Department of Surgery, Tongji Hospital of Huazhong Science & Technology University, Wuhan 430030, China.
Zhonghua Zhong Liu Za Zhi. 2009 Nov;31(11):804-9.
To investigate the changes in cell cycle induced by cisplatin (DDP) and the effect of antisense oligonucleotide (AsODN) targeting Chk1/2 on DDP-induced apoptosis in lung cancer cell line A549 cells.
The characteristics of cell cycle and apoptosis induced by DDP were detected by flow cytometry using SubG1 method. Chk1/2 mRNA and protein expression were assayed by RT-PCR and Western blot under best condition of transfection of AsODN targeting Chk1/2 by lipofection. Apoptosis of A549 cells induced by DDP was determined by flow cytometry using AnnexinV-FITC staining after transfection of Chk1/2 AsODN.
Asynchronized A549 cells were treated with 10 micromol/L DDP, and significant S-phase arrest was observed at 12 h later. Transfection with antisense oligonucleotide targeting Chk1/2 inhibited the Chk1/2 expression at both mRNA and protein levels. Either Chk1 or Chk2-specific AsODN consistently enhanced DNA damage-induced apoptosis by 100% - 200%, compared with that in the sODN control (P < 0.05), but combined use of Chk1- and Chk2-specific AsODN did not show synergistic effects as compared with that induced by treatment with Chk1- or Chk2-specific AsODN alone (P > 0.05).
Chk1 and Chk2 may be regarded as effective targets of chemotherapy for lung cancer. Silencing the key effector Chk1 and Chk2 genes may significantly increase the chemosensitivity of lung cancer cells.
探讨顺铂(DDP)诱导的肺癌细胞系A549细胞周期变化以及靶向Chk1/2的反义寡核苷酸(AsODN)对DDP诱导凋亡的影响。
采用流式细胞术SubG1法检测DDP诱导的细胞周期特征及凋亡情况。在脂质体转染靶向Chk1/2的AsODN的最佳条件下,用RT-PCR和蛋白质印迹法检测Chk1/2 mRNA和蛋白表达。转染Chk1/2 AsODN后,采用AnnexinV-FITC染色的流式细胞术检测DDP诱导的A549细胞凋亡。
用10 μmol/L DDP处理同步化的A549细胞,12小时后观察到明显的S期阻滞。转染靶向Chk1/2的反义寡核苷酸在mRNA和蛋白水平均抑制Chk1/2表达。与正义寡核苷酸(sODN)对照相比,Chk1或Chk2特异性AsODN均使DNA损伤诱导的凋亡增加100% - 200%(P < 0.05),但Chk1和Chk2特异性AsODN联合使用与单独使用Chk1或Chk2特异性AsODN诱导的凋亡相比无协同作用(P > 0.05)。
Chk[1]和Chk2可被视为肺癌化疗的有效靶点。沉默关键效应基因Chk1和Chk2可能显著提高肺癌细胞的化疗敏感性。